Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

68.14USD
12 Dec 2018
Change (% chg)

$0.42 (+0.62%)
Prev Close
$67.72
Open
$68.58
Day's High
$69.32
Day's Low
$68.06
Volume
6,447,976
Avg. Vol
6,783,597
52-wk High
$89.54
52-wk Low
$64.27

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $87,241.70
Shares Outstanding(Mil.): 1,293.62
Dividend: 0.57
Yield (%): 3.38

Financials

  GILD.O Industry Sector
P/E (TTM): 12.50 95.96 30.88
EPS (TTM): 5.40 -- --
ROI: 13.07 0.60 13.80
ROE: 29.64 -2.18 15.29

Gilead Sciences snares Roche veteran O'Day as CEO

Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.

Dec 10 2018

UPDATE 4-Gilead Sciences snares Roche veteran O'Day as CEO

* William Anderson to replace O'Day as Roche Pharmaceuticals CEO

Dec 10 2018

Gilead Sciences to hire Roche executive O'Day as new CEO -source

Dec 9 Drugmaker Gilead Sciences Inc will name Roche Holding AG executive Daniel O'Day as its new chief executive officer, according to a source familiar with the matter.

Dec 09 2018

BRIEF-Gilead Sciences Plans To Hire Daniel O'Day As Its Next CEO - WSJ

* DRUGMAKER GILEAD SCIENCES PLANS TO HIRE DANIEL O'DAY AS ITS NEXT CEO - WSJ, CITING SOURCES Source text : https://on.wsj.com/2C1oCCN Further company coverage:

Dec 09 2018

J&J unit to pay $360 million to U.S. to resolve charity kickback probe

BOSTON A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.

Dec 06 2018

UPDATE 3-J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.

Dec 06 2018

J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A unit of Johnson & Johnson has agreed to pay the U.S. government $360 million to resolve an investigation into its financial support of charities that help Medicare patients cover out-of-pocket drug costs, the U.S. Justice Department said on Thursday.

Dec 06 2018

High-cost Gilead cell therapy proves durable for some lymphoma patients

(This December 2 story corrects spelling in paragraph 5 to Alvarnas from Alvarnaz)

Dec 03 2018

CORRECTED-UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients

SAN DIEGO, Dec 2 Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday.

Dec 03 2018

At 2 years, Gilead lymphoma therapy active in 40 pct of patients

SAN DIEGO, Dec 2 Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday.

Dec 02 2018

Earnings vs. Estimates